

*Variant: NM_001040142.2(SCN2A):c.3043G>A
(p.Asp1015Asn)*

Version: 1.0

CA10612411 [↗](#)

331730 (ClinVar) [↗](#)

Gene: SCN2A ([HGNC:6326](#))

Condition: complex neurodevelopmental disorder ([MONDO:0100038](#))

Inheritance Mode: Autosomal dominant inheritance

UID: 8266754d-3fb0-4c99-9635-ead230befadc

Approved on: 2024-11-26

Published on: 2024-12-19

HGVS expressions

NM_001040142.2:c.3043G>A

NM_001040142.2(SCN2A):c.3043G>A (p.Asp1015Asn)

NC_000002.12:g.165354315G>A

CM000664.2:g.165354315G>A

NC_000002.11:g.166210825G>A

CM000664.1:g.166210825G>A

NC_000002.10:g.165919071G>A

NG_008143.1:g.119914G>A

ENST00000631182.3:c.3043G>A

ENST00000375437.7:c.3043G>A

ENST00000636071.2:c.3043G>A

ENST00000636135.1:c.*1362G>A

ENST00000636384.2:c.*1030G>A

ENST00000636662.2:c.*3566G>A

ENST00000636769.1:c.*985G>A

ENST00000636985.2:c.2647G>A

ENST00000637266.2:c.3043G>A

ENST00000673831.1:c.789G>A

ENST00000673883.1:c.608G>A

ENST00000674133.1:c.894G>A

ENST00000283256.10:c.3043G>A

ENST00000375427.4:c.3043G>A

ENST00000375437.6:c.3043G>A

ENST00000480032.4:n.3186G>A

ENST00000631182.2:c.3043G>A

NM_001040142.1:c.3043G>A

NM_001040143.1:c.3043G>A

NM_021007.2:c.3043G>A

NM_001040143.2:c.3043G>A

NM_001371246.1:c.3043G>A

NM_001371247.1:c.3043G>A

NM_021007.3:c.3043G>A

Likely Benign

Met criteria codes 4

PS4_Supporting BS1 BP4

PM6_Supporting

Not Met criteria codes 11

PS1 PS3 BA1 PP1 PP3

PM1 PM5 PM2 BS2 BP2

BP5

Evidence Links 0

Expert Panel

Epilepsy Sodium Channel VCEP

Criteria Specification Information

[Criteria Specification](#): ClinGen Epilepsy Sodium Channel Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for SCN2A Version 1.0.0

[Criteria Specification Approval History](#)









[Criteria Specifications for this VCEP](#)

Evidence submitted by expert panel






















Epilepsy Sodium Channel VCEP


The NM_001040142.2:c.3043G>A variant in SCN2A is a missense variant predicted to cause substitution of Aspartic Acid by Asparagine at amino acid 1015 (p.Asp1015Asn). This variant has been reported in one proband meeting phenotypic criteria for Complex Neurodevelopmental Disorder (MONDO:0100038) (PS4_Supporting; PMID 30564305); however, this variant was inherited from a parent whose affected status is unknown. This variant was also found to occur de novo in one proband meeting criteria for Complex Neurodevelopmental Disorder (MONDO:0100038) with unconfirmed parental relationships (PM6_Supporting; PMID 35431799). The minor allele frequency in the European (non-Finnish) genetic ancestry group in gnomAD v4.1.0 is 0.000006780 (0.0007%, or 8/1179964 alleles), which is higher than the ClinGen Epilepsy Sodium Channel threshold (>0.0002%) for BS1, and therefore meets this criterion (BS1). The computational predictor REVEL gives a score of 0.287, which is below the threshold of 0.290, evidence that does not predict a damaging effect on SCN2A function (BP4). In summary, this variant meets the criteria to be classified as likely benign for autosomal dominant Complex Neurodevelopmental Disorder. Although there are both pathogenic and benign types of evidence for this variant, the pathogenic evidence is not considered inconsistent with the final classification. ACMG/AMP criteria applied, as specified by the ClinGen Epilepsy Sodium Channel VCEP: PS4_Supporting, PM6_Supporting, BP4, BS1. (Epilepsy Sodium Channel VCEP Specifications version 1.0.0; Approved 1/26/2024).

Met criteria codes

PS4_Supporting			This variant has been reported in one proband meeting phenotypic criteria for Complex Neurodevelopmental Disorder (MONDO:0100038) (PS4_Supporting; PMID 30564305).
BS1			The minor allele frequency in the European (non-Finnish) genetic ancestry group in gnomAD v4.1.0 is 0.000006780 (0.0007%, or 8/1179964 alleles), which is higher than the ClinGen Epilepsy Sodium Channel threshold (>0.0002%) for BS1, and therefore meets this criterion. Other genetic ancestry groups (East Asian and South Asian) have higher allele frequencies but do not meet the ClinGen Epilepsy Sodium Channel threshold of ≥ 5 alleles to meet this criterion (BS1).
BP4			The computational predictor REVEL gives a score of 0.287, which is below the threshold of 0.290, evidence that does not predict a damaging effect on SCN2A function (BP4).
PM6_Supporting			This variant has been identified as a de novo occurrence with unconfirmed parental relationships in 1 individual meeting phenotypic criteria for Complex Neurodevelopmental Disorder (MONDO:0100038) (PM6_Supporting; PMID 35431799).

Not Met criteria codes

PS1			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS3			To our knowledge, functional assays have not been reported for this variant.
BA1			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PP1			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PP3			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM1			This variant does not reside within a region of SCN2A that is defined as a mutational hotspot or critical functional domain by the ClinGen Epilepsy Sodium Channel VCEP.
PM5			Two different missense variants, c.3043G>C (p.Asp1015His) and c.3043G>T (p.Asp1015Tyr), in the same codon have been reported in ClinVar (ClinVar IDs: 2068042, 1036643). However, these variants have not yet met the criteria to be classified as pathogenic or likely pathogenic by the ClinGen Epilepsy Sodium Channel VCEP.
PM2			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS2			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP2			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP5			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline

[Curation History](#) 

	▼	▼
--	---	---

Showing 1 to 1 of 1 rows

--

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.